Immunology Devices Panel of the Medical Devices Advisory Committee: Notice of Postponement of Meeting, 55398 [2011-22767]
Download as PDF
<![CDATA[
emcdonald on DSK5VPTVN1PROD with NOTICES
55398
Federal Register / Vol. 76, No. 173 / Wednesday, September 7, 2011 / Notices
4:30 p.m. Those individuals interested
in making formal oral presentations
should notify the contact person and
submit a brief statement of the general
nature of the evidence or arguments
they wish to present, the names and
addresses of proposed participants, and
an indication of the approximate time
requested to make their presentation on
or before November 1, 2011. Time
allotted for each presentation may be
limited. If the number of registrants
requesting to speak is greater than can
be reasonably accommodated during the
scheduled open public hearing session,
FDA may conduct a lottery to determine
the speakers for the scheduled open
public hearing session. The contact
person will notify interested persons
regarding their request to speak by
November 2, 2011.
Closed Committee Deliberations: On
November 16, 2011, between
approximately 9:45 a.m. and 10:15 a.m.,
the meeting will be closed to permit
discussion where disclosure would
constitute a clearly unwarranted
invasion of personal privacy (5 U.S.C.
552b(c)(6)). The committee will discuss
the report of the intramural research
program in the Laboratory of Method
Development and make
recommendations regarding personnel
staffing decisions.
Persons attending FDA’s advisory
committee meetings are advised that the
Agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with physical
disabilities or special needs. If you
require special accommodations due to
a disability, please contact Donald W.
Jehn or Denise Royster at least 7 days in
advance of the meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our Web site at
https://www.fda.gov/Advisory
Committees/AboutAdvisoryCommittees/
ucm111462.htm for procedures on
public conduct during advisory
committee meetings.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: August 31, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy
[FR Doc. 2011–22766 Filed 9–6–11; 8:45 am]
BILLING CODE 4160–01–P
VerDate Mar<15>2010
17:37 Sep 06, 2011
Jkt 223001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2011–N–0002]
Immunology Devices Panel of the
Medical Devices Advisory Committee:
Notice of Postponement of Meeting
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is postponing the
meeting of the Immunology Devices
Panel of the Medical Devices Advisory
Committee scheduled for October 14,
2011. The meeting was announced in
the Federal Register of August 9, 2011
(76 FR 48871). The meeting is
postponed so that FDA can review and
consider additional information that
was submitted. Future meeting dates
will be announced in the Federal
Register.
FOR FURTHER INFORMATION CONTACT:
Shanika Craig, Center for Devices and
Radiological Health, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 66, rm. 1613, Silver Spring,
MD 20993–0002, 301–796–6639, e-mail:
shanika.craig@fda.hhs.gov, or FDA
Advisory Committee Information Line,
1–800–741–8138 (301–443–0572 in the
Washington, DC area). Please call the
Information Line for up-to-date
information on this meeting.
SUMMARY:
Dated: August 31, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2011–22767 Filed 9–6–11; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Agency Information Collection
Activities: Proposed Collection;
Comment Request; Generic Clearance
for the Collection of Qualitative
Feedback on Agency Service Delivery
National Institutes of Health,
Eunice Kennedy Shriver National
Institute of Child Health and Human
Development (NICHD), HHS.
ACTION: 30-Day notice of submission of
information collection approval from
the Office of Management and Budget
and request for comments.
AGENCY:
As part of a Federal
Government-wide effort to streamline
the process to seek feedback from the
SUMMARY:
PO 00000
Frm 00054
Fmt 4703
Sfmt 4703
public on service delivery, NICHD has
submitted a Generic Information
Collection Request (Generic ICR):
‘‘Generic Clearance for the Collection of
Qualitative Feedback on Agency Service
Delivery ’’ to OMB for approval under
the Paperwork Reduction Act (PRA) (44
U.S.C. 3501 et seq.).
DATES: Comments must be submitted
within 30 days after publication in FR.
ADDRESSES: Written comments may be
submitted to the Office of Management
and Budget, Office of Information and
Regulatory Affairs, Attn: NIH Desk
Officer, by E-mail to
OIRA_submission@omb.eop.gov, or by
fax to 202–395–6974.
FOR FURTHER INFORMATION CONTACT: To
request additional information, please
contact Ms. Jamelle Banks, Public
Health Analyst, Office of Science Policy,
Analysis and Communication, National
Institute of Child Health and Human
Development, 31 Center Drive Room
2A18, Bethesda, Maryland 20892, or call
a non-toll free number (301) 496–1877
or E-mail your request, including your
address to banksj@mail.nih.gov.
SUPPLEMENTARY INFORMATION:
Title: Generic Clearance for the
Collection of Qualitative Feedback on
Agency Service Delivery.
Abstract: The information collection
activity will garner qualitative customer
and stakeholder feedback in an efficient,
timely manner, in accordance with the
Administration’s commitment to
improving service delivery. By
qualitative feedback we mean
information that provides useful
insights on perceptions and opinions,
but are not statistical surveys that yield
quantitative results that can be
generalized to the population of study.
This feedback will provide insights into
customer or stakeholder perceptions,
experiences and expectations, provide
an early warning of issues with service,
or focus attention on areas where
communication, training or changes in
operations might improve delivery of
products or services. These collections
will allow for ongoing, collaborative and
actionable communications between the
Agency and its customers and
stakeholders. It will also allow feedback
to contribute directly to the
improvement of program management.
Feedback collected under this generic
clearance will provide useful
information, but it will not yield data
that can be generalized to the overall
population. This type of generic
clearance for qualitative information
will not be used for quantitative
information collections that are
designed to yield reliably actionable
results, such as monitoring trends over
E:\FR\FM\07SEN1.SGM
07SEN1
]]>Agencies
[Federal Register Volume 76, Number 173 (Wednesday, September 7, 2011)]
[Notices]
[Page 55398]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-22767]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2011-N-0002]
Immunology Devices Panel of the Medical Devices Advisory
Committee: Notice of Postponement of Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is postponing the
meeting of the Immunology Devices Panel of the Medical Devices Advisory
Committee scheduled for October 14, 2011. The meeting was announced in
the Federal Register of August 9, 2011 (76 FR 48871). The meeting is
postponed so that FDA can review and consider additional information
that was submitted. Future meeting dates will be announced in the
Federal Register.
FOR FURTHER INFORMATION CONTACT: Shanika Craig, Center for Devices and
Radiological Health, Food and Drug Administration, 10903 New Hampshire
Ave., Bldg. 66, rm. 1613, Silver Spring, MD 20993-0002, 301-796-6639,
e-mail: shanika.craig@fda.hhs.gov, or FDA Advisory Committee
Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC
area). Please call the Information Line for up-to-date information on
this meeting.
Dated: August 31, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2011-22767 Filed 9-6-11; 8:45 am]
BILLING CODE 4160-01-P
